2020
DOI: 10.1001/jama.2020.21974
|View full text |Cite
|
Sign up to set email alerts
|

Managing Asthma in Adolescents and Adults

Abstract: IMPORTANCEAsthma is a major public health problem worldwide and is associated with excess morbidity, mortality, and economic costs associated with lost productivity. The National Asthma Education and Prevention Program has released the 2020 Asthma Guideline Update with updated evidence-based recommendations for treatment of patients with asthma.OBJECTIVE To report updated recommendations for 6 topics for clinical management of adolescents and adults with asthma: (1) intermittent inhaled corticosteroids (ICSs);… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
49
0
1

Year Published

2020
2020
2023
2023

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 114 publications
(53 citation statements)
references
References 73 publications
(148 reference statements)
0
49
0
1
Order By: Relevance
“…These effects are reinforced when glycopyrronium is used in combination with formoterol and budesonide in vitro ( 27 , 37 ). Nonetheless, glycopirronium is not routinely used in children and more studies are needed to better understand if asthma treatment could really be considered protective against SARS-COV-2 infection ( 27 , 51 ).…”
Section: Discussionmentioning
confidence: 99%
“…These effects are reinforced when glycopyrronium is used in combination with formoterol and budesonide in vitro ( 27 , 37 ). Nonetheless, glycopirronium is not routinely used in children and more studies are needed to better understand if asthma treatment could really be considered protective against SARS-COV-2 infection ( 27 , 51 ).…”
Section: Discussionmentioning
confidence: 99%
“…Recently, LAMAs, initially tiotropium, later glycopyrronium and umeclidinium, have been studied as add-on therapy in patients with asthma, and particularly in patients who have persistent asthma symptoms or exacerbations despite optimised inhaled corticosteroid (ICS)/ LABA treatment [7]. Indeed, both the Global Initiative for Asthma (GINA) strategy document and the National Asthma Education and Prevention Program guideline position tiotropium before biologic drugs or oral corticosteroids (OCS) [10,11]. In addition, the European Respiratory Society (ERS)/American Thoracic Society (ATS) Severe Asthma Task Force recommends tiotropium as an add-on to ICS/LABA in patients with severe asthma regardless of phenotype [12].…”
Section: Introductionmentioning
confidence: 99%
“…However, only SLIT showed clinical improvement related to Tregs (Xian et al, 2020). Despite these results, SCIT is just recommended as an adjunct to pharmacotherapy in individuals with asthma, and SLIT is not recommended (Cloutier et al, 2020).…”
Section: Immune Cell Treatment: T-cellsmentioning
confidence: 98%